Relevance of urine telomerase in the diagnosis of bladder cancer

JAMA

Volumn 294, Issue 16, 2005, Pages 2052-2056

  Sanchini, Maria Aurora ^a   Gunelli, Roberta ^a   Nanni, Oriana ^b   Bravaccini, Sara ^a   Fabbri, Carla ^c   Sermasi, Alice ^c   Bercovich, Eduard ^a   Ravaioli, Alberto ^c   Amadori, Dino ^d   Calistri, Daniele ^a  

^a MORGAGNI PIERANTONI HOSPITAL   (Italy)

^b ISTITUTO ONCOLOGICO ROMAGNOLO   (Italy)

^c INFERMI HOSPITAL   (Italy)

^d DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

TELOMERASE; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER DIAGNOSIS; CANCER SCREENING; CASE CONTROL STUDY; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTOSCOPY; CYTOLOGY; DIAGNOSTIC ACCURACY; ENZYME ACTIVITY; HISTOPATHOLOGY; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MICTURITION; PILOT STUDY; PREDICTION; PRIORITY JOURNAL; TELOMERIC REPEAT AMPLIFICATION PROTOCOL; URINALYSIS; VALIDATION PROCESS; BLADDER TUMOR; ENZYMOLOGY; MASS SCREENING; MIDDLE AGED; NUCLEIC ACID AMPLIFICATION; SENSITIVITY AND SPECIFICITY; URINE; VALIDATION STUDY;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; NUCLEIC ACID AMPLIFICATION TECHNIQUES; SENSITIVITY AND SPECIFICITY; TELOMERASE; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; URINE;

EID: 27244433839     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.294.16.2052     Document Type: Article

References (46)

1. American Cancer Society. Cancer Facts and Figures 2004. Atlanta, Ga: American Cancer Society; 2004.
2. Johansson SL, Cohen SM. Epidemiology and etiology of bladder cancer. Semin Surg Oncol. 1997;13:291-298.
3. National Cancer Institute Web site. General information about bladder cancer. Available at: http://seer.cancer.gov/publications/ethnicity/bladder.pdf. Accessed September 2, 2005.
4. Messing EM, Young TB, Hunt VB, et al. Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations. Urology. 1995;45:387-396.
5. Herr HW, Shipley WU, Bajorin DF. Cancer of the bladder. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 6th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001:1396-1418.
6. Kinoshita H, Ogawa O, Kakehi Y, et al. Detection of telomerase activity in exfoliated cells in urine from patients with bladder cancer. J Natl Cancer Inst. 1997;89:724-730.
7. Yoshida K, Sugino T, Tahara H, et al. Telomerase activity in bladder carcinoma and its implication for noninvasive diagnosis by detection of exfoliated cancer cells in urine. Cancer. 1997;79:362-369.
8. Muller M, Krause H, Heicappell R, Tischendorf J, Shay JW, Miller K. Comparison of human telomerase RNA and telomerase activity in urine for diagnosis of bladder cancer. Clin Cancer Res. 1998;4:1949-1954.
9. Dalbagni G, Han W, Zhang ZF, et al. Evaluation of the telomeric repeat amplification protocol (TRAP) assay for telomerase as a diagnostic modality in recurrent bladder cancer. Clin Cancer Res. 1997;3:1593-1598.
10. Ramakumar S, Bhuiyan J, Besse JA, et al. Comparison of screening methods in the detection of bladder cancer. J Urol. 1999;161:388-394.
11. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266:2011-2015.
12. Hirose M, Abe-Hashimoto J, Ogura K, et al. A rapid, useful and quantitative method to measure telomerase activity by hybridization protection assay connected with a telomeric repeat amplification protocol. J Cancer Res Clin Oncol. 1997;123:337-344.
13. Kim NW, Wu F. Advances in quantification and characterization of telomerase activity by the telomeric repeat amplification protocol (TRAP). Nucleic Acids Res. 1997;25:2595-2597.
14. Gelmini S, Caldini A, Becherini L, et al. Rapid, quantitative nonisotopic assay for telomerase activity in human tumors. Clin Chem. 1998;44:2133-2138.
15. Yahata N, Ohyashiki K, Ohyashiki JH, et al. Telomerase activity in lung cancer cells obtained from bronchial washings. J Natl Cancer Inst. 1998;90:684-690.
16. Lin Y, Miyamoto H, Fujinami K, et al. Telomerase activity in human bladder cancer. Clin Cancer Res. 1996;2:929-932.
17. Wright WE, Shay JW, Piatyszek MA. Modifications of a telomeric repeat amplification protocol (TRAP) result in increased reliability, linearity and sensitivity. Nucleic Acids Res. 1995;23:3794-3795.
18. Sanchini MA, Bravaccini S, Medri L, et al. Urine telomerase: an important marker in the diagnosis of bladder cancer. Neoplasia. 2004;6:234-239.
19. Fedriga R, Gunelli R, Nanni O, Bacci F, Amadori D, Calistri D. Telomerase activity detected by quantitative assay in bladder carcinoma and exfoliated cells in urine. Neoplasia. 2001;3:446-450.
20. Deeks JJ. Systematic reviews in health care: systematic reviews of evaluations of diagnostic and screening tests. BMJ. 2001;323:157-162.
21. Hiyama E, Gollahon L, Kataoka T, et al. Telomerase activity in human breast tumors. J Natl Cancer Inst. 1996;88:116-122.
22. Breslow RA, Shay JW, Gazdar AF, Srivastava S. Telomerase and early detection of cancer. J Natl Cancer Inst. 1997;89:618-623.
23. Shay JW, Gazdar AF. Telomerase in the early detection of cancer. J Clin Pathol. 1997;50:106-109.
24. Tatsumoto N, Hiyama E, Murakami Y, et al. High telomerase activity is an independent prognostic indicator of poor outcome in colorectal cancer. Clin Cancer Res. 2000;6:2696-2701.
25. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer. 1997;33:787-791.
26. Califano J, Ahrendt SA, Meininger G, Westra WH, Koch WM, Sidransky D. Detection of telomerase activity in oral rinses from head and neck squamous cell carcinoma patients. Cancer Res. 1996;56:5720-5722.
27. Kannan S, Tahara H, Yokozaki H, et al. Telomerase activity in premalignant and malignant lesions of human oral mucosa. Cancer Epidemiol Biomarkers Prev. 1997;6:413-420.
28. Mutirangura A, Supiyaphun P, Trirekapan S, et al. Telomerase activity in oral leukoplakia and head and neck squamous cell carcinoma. Cancer Res. 1996;56:3530-3533.
29. Miyoshi Y, Tsukinoki K, Imaizumi T, et al. Telomerase activity in oral cancer. Oral Oncol. 1999;35:283-289.
30. Holt SE, Shay JW. Role of telomerase in cellular proliferation and cancer. J Cell Physiol. 1999;180:10-18.
31. Keesee SK, Briggman JV, Thill G, Wu YJ. Utilization of nuclear matrix protein for cancer diagnosis. Crit Rev Eukaryot Gene Expr. 1996;6:189-214.
32. Getzenberg RH, Konety BR, Oeler TA, et al. Bladder cancer-associated nuclear matrix proteins. Cancer Res. 1996;56:1690-1694.
33. Sarosdy MF, Hudson MA, Ellis WJ, et al. Improved detection of recurrent bladder cancer using the Bard BTA stat test. Urology. 1997;50:349-353.
34. Sharma S, Zippe CD, Pandrangi L, Nelson D, Agarwal A. Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. J Urol. 1999;162:53-57.
35. Konety BR, Getzenberg RH. Urine based markers of urological malignancy. J Urol. 2001;165:600-611.
36. Kausch I, Böhle A. Bladder cancer, II: molecular aspects and diagnosis. Eur Urol. 2001;39:498-506.
37. Lokeshwar VB, Soloway MS. Current bladder tumor tests: does their projected utility fulfill clinical necessity? J Urol. 2001;165:1067-1077.
38. Glas AS, Roos D, Deutekom M, et al. Tumor markers in the diagnosis of primary bladder cancer: a systematic review. J Urol. 2003;169:1975-1982.
39. Grossman HB, Messing E, Soloway M, et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA. 2005;293:810-816.
40. Halling KC, King W, Sokolova IA, et al. A comparison of cytology and fluorescence in situ hybridization (FISH) for the detection of urothelial carcinoma. J Urol. 2000;164:1768-1775.
41. Halling KC, King W, Sokolova IA, et al. A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis Urovysion assays for the detection of urothelial carcinoma in urine. J Urol. 2002;167:2001-2006.
42. Sarosdy MF, Schellhammer P, Bokinsky G, et al. Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol. 2002;168:1950-1954.
43. Placer J, Espinet B, Salido M, Solé F, Gelabert-Mas A. Clinical utility of a multiprobe FISH assay in voided urine specimens for the detection of bladder cancer and its recurrences, compared to urinary cytology. Eur Urol. 2002;42:547-552.
44. Sourvinos G, Kazanis I, Delakas D, Cranidis A, Spandidos DA. Genetic detection of bladder cancer by microsatellite analysis of p16, RB1 and p53 tumor suppressor genes. J Urol. 2001;165:249-252.
45. Dulaimi E, Uzzo RG, Greenberg RE, Al-Saleem T, Cairns P. Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel. Clin Cancer Res. 2004;10:1887-1893.
46. Smith SD, Wheeler MA, Plescia J, Colberg JW, Weiss RM, Altieri DC. Urine detection of survivin and diagnosis of bladder cancer. JAMA. 2001;285:324-328.